Medtronic Sees Unusually High Options Volume (NYSE:MDT)

Medtronic PLC (NYSE:MDT) was the recipient of unusually large options trading activity on Wednesday. Traders bought 143,524 call options on the stock. This represents an increase of approximately 1,013% compared to the typical volume of 12,892 call options.

Medtronic Price Performance

Shares of NYSE MDT opened at $97.31 on Thursday. Medtronic has a 52 week low of $79.29 and a 52 week high of $106.33. The business’s 50 day moving average price is $97.48 and its 200 day moving average price is $93.64. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The firm has a market cap of $124.75 billion, a P/E ratio of 26.23, a P/E/G ratio of 2.57 and a beta of 0.71.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same period last year, the firm posted $1.26 EPS. Medtronic’s revenue for the quarter was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts expect that Medtronic will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be issued a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Friday, December 26th. Medtronic’s dividend payout ratio is presently 76.55%.

Hedge Funds Weigh In On Medtronic

A number of institutional investors have recently modified their holdings of MDT. Corundum Trust Company INC acquired a new stake in Medtronic during the third quarter worth about $27,000. 1248 Management LLC purchased a new stake in Medtronic in the 1st quarter worth approximately $26,000. Valley Wealth Managers Inc. acquired a new stake in shares of Medtronic during the 3rd quarter worth approximately $29,000. Delos Wealth Advisors LLC acquired a new stake in shares of Medtronic during the 2nd quarter worth approximately $27,000. Finally, Imprint Wealth LLC purchased a new position in shares of Medtronic during the 3rd quarter valued at approximately $31,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on MDT shares. Citigroup raised their target price on shares of Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. Wall Street Zen upgraded Medtronic from a “hold” rating to a “buy” rating in a report on Saturday, December 20th. Royal Bank Of Canada boosted their target price on Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. The Goldman Sachs Group set a $111.00 target price on Medtronic and gave the company a “neutral” rating in a research report on Wednesday, November 19th. Finally, UBS Group raised their price target on Medtronic from $95.00 to $102.00 and gave the stock a “neutral” rating in a report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $109.94.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).